Replies to post #545894 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

No I did not know it, as most all is wrong.

If you read the ORBIS site, it is very clear the path follows the FDA staff review.

On cost neutral you are correct it does take into account how a drug can reduce future burden on the system. Since most all patients are still failing, that is not going to make up for the upfront cost.

On rGBM you are somewhat right. Of course the rGBM concept has huge issues. They have trial data on DCVax-L made at nGBM surgery being used only after waiting for progression or psPD. Hard to see a clinical reality there.